MEDI0457 was studied in combination with anti-PDL1 durvalumab in a phase Ib/IIa trial in 35 patients with HPV-associated, ICI -naïve R/M HNSCC who had progressed on at least one prior regimen (14). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.